Clinical trial
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head…
NCT00113347 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00113347 |
|---|---|
| Title | Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Official title | Phase I Evaluation of Erlotinib and Docetaxel With Concomitant Boost Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Aventis Pharmaceuticals Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Erlotinib, Docetaxel, Radiation Therapy |
| Enrollment | 10 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jun 8, 2005 |
| Last update posted | Feb 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: